Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

t Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has received acceptance notification for two presentations of results from its Ultrafast Insulin studies at this year's ADA. A poster presentation examines the role that the coinjection of rHuPH20 with prandial insulin plays in the acceleration of pharmacokinetics and glucodynamics across a variety of populations. The second data set to be presented utilizes continuous glucose monitoring over a 72-hour period to test the variability of insulin absorption with and without rHuPH20 at the beginning and the end of a 12-week treatment study. The goal of Halozyme's Ultrafast Insulin program is to develop a best-in-class mealtime insulin product compared to the currently prescribed analogs that participate in the growing $3.8 billion worldwide prandial insulin market.

First Quarter 2011 Financial ResultsThe net loss for the first quarter of 2011 was $9.6 million, or $0.10 per share, compared with a net loss for the first quarter of 2010 of $11.8 million, or $0.13 per share.

  • Revenue for the first quarter of 2011 was $7.5 million, compared to $3.4 million for the first quarter of 2010. Revenues under collaborative agreements for the first quarter of 2011 were $7.4 million, compared to $3.0 million for the first quarter of 2010. Revenues under collaborative agreements in the first quarter of 2011 primarily consisted of a milestone payment and the amortization of upfront payments received from Baxter and Roche of $5.7 million and research and development reimbursements from Baxter and Roche of $1.6 million.
  • Research and development expenses for the first quarter of 2011 were $13.8 million, compared with $11.5 million for the first quarter of 2010, primarily due to an increase in clinical trial activities supporting the Ultrafast Insulin program.  
  • Selling, general and administrative expenses for the first quarter of 2011 were $3.4 million, compared to $3.8 million
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    (Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
    (Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
    (Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
    Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
    ... September when Vioxxs manufacturer removed the drug from the ... Drug Administration and the pharmaceutical industry faced a bumpy ... the pipeline problem, the slowdown instead of the ... In its March 2004 Critical Path report, FDA ...
    ... about integrating technology with patient care at the Digital ... in Madison. Academic and medical experts discussed technologies which ... installation, as well as the multiple roadblocks to successful ... the fact that technology for technology's sake is a ...
    ... was appointed as regional director for Region 5 of ... the representative of HHS Secretary Michael Leavitt, handling all ... , ,OBrien is the former chief of staff for ... director of public affairs for the manufacturing company IMC ...
    Cached Biology Technology:Challenging times for FDA and drug companies equals IT opportunities 2Challenging times for FDA and drug companies equals IT opportunities 3Digitizing hospitals with the right tools 2Digitizing hospitals with the right tools 3Digitizing hospitals with the right tools 4
    (Date:12/22/2014)... , Dec. 22, 2014  The 2014 ... the biometrics industry as Acuity Market Intelligence reports ... may finally be open. Acuity forecasts that intensifying ... devices that incorporate biometrics will drive a global ... billion biometric devices by 2020.   ...
    (Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
    (Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
    Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
    ... at WEHI into a possible new cancer drug suggests ... less toxic than current chemotherapeutic drugs. , Dr David ... teams from WEHI's cancer research divisions have been assessing ... developed by US-based healthcare company, Abbott. , ...
    ... around the world keep a nervous eye on the spread ... Disease Organization (VIDO) has uncovered a key step in how ... team have discovered how a crucial pathway that supports the ... finding that could pave the way for new drugs and ...
    ... get lab results back from the doctor's office soon could ... of University of Georgia researchers has developed a diagnostic test ... RSV in 60 seconds or less. , In addition to ... issue of the journal Nano Letters ?could save lives by ...
    Cached Biology News:Hope for a more effective and less toxic cancer drug 2U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 3
    Request Info...
    ...
    ... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
    Request Info...
    Biology Products: